Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reiferon Retard and Ribavirin in Egyptian Children with Chronic Hepatitis C
NCT02027493Completed
- Sponsor
- National Liver Institute
- Start
- Feb 2009
- Primary completion
- Jan 2011
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (2 arms), sponsored by National Liver Institute. Primary endpoints: Safety of Hansenula-Derived Pegylated-Interferon Alpha-2a at 48 weeks and Sustained Virological Response at 48 weeks. Started Feb 2009; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02027493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027493.